Dupix­ent wins EU la­bel ex­pan­sion in COPD ahead of de­layed FDA de­ci­sion

Sanofi and Re­gen­eron’s Dupix­ent has notched an­oth­er in­di­ca­tion in the EU, this time for a com­mon lung dis­ease, mark­ing the first-ever tar­get­ed ther­a­py for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER